Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Change in Account Payables (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Change in Account Payables for 4 consecutive years, with -$50580.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 104.04% to -$50580.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$527006.0 through Dec 2025, down 210.38% year-over-year, with the annual reading at -$527006.0 for FY2025, 210.38% down from the prior year.
  • Change in Account Payables hit -$50580.0 in Q4 2025 for Coya Therapeutics, down from $180358.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.3 million in Q4 2024 to a low of -$1.5 million in Q3 2024.
  • Historically, Change in Account Payables has averaged $68409.0 across 4 years, with a median of $141118.5 in 2025.
  • Biggest five-year swings in Change in Account Payables: surged 654.03% in 2023 and later plummeted 475.92% in 2024.
  • Year by year, Change in Account Payables stood at $389106.0 in 2022, then increased by 22.52% to $476727.0 in 2023, then surged by 162.5% to $1.3 million in 2024, then crashed by 104.04% to -$50580.0 in 2025.
  • Business Quant data shows Change in Account Payables for COYA at -$50580.0 in Q4 2025, $180358.0 in Q3 2025, and -$758663.0 in Q2 2025.